According to DexCom's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 67.6531. At the end of 2022 the company had a P/E ratio of 129.
Year | P/E ratio | Change |
---|---|---|
2022 | 129 | -49.43% |
2021 | 254 | 258.6% |
2020 | 71.0 | -64.64% |
2019 | 201 | -341.22% |
2018 | -83.2 | -14.47% |
2017 | -97.3 | 27.09% |
2016 | -76.5 | -31.78% |
2015 | -112 | -38.86% |
2014 | -184 | 117.65% |
2013 | -84.3 | 390.1% |
2012 | -17.2 | 25.65% |
2011 | -13.7 | -0.7% |
2010 | -13.8 | 105.02% |
2009 | -6.73 | 387.32% |
2008 | -1.38 | -74.68% |
2007 | -5.45 | -5.47% |
2006 | -5.77 | 31.79% |
2005 | -4.38 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.